

Sven Stodtman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6217266/publications.pdf>

Version: 2024-02-01

8
papers

68
citations

1684188
5
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

68
citing authors

#	ARTICLE	IF	CITATIONS
1	Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 68-72.	2.2	11
2	An Exposureâ€Response Model with Timeâ€Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCAâ€Mutated Advanced Breast Cancer (BROCADE3) Trial. <i>Journal of Clinical Pharmacology</i> , 2022, , .	2.0	3
3	Bridging Fixed Dose to Body Weight-based Regimen of Adalimumab in Paediatric Ulcerative Colitis Using a Pharmacometric Modelling Approach: Case Study with the Phase 3 ENVISION I Trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1551-1561.	1.3	1
4	Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis. <i>Clinical and Translational Science</i> , 2021, 14, 1611-1619.	3.1	3
5	A Population Pharmacokinetic Metaâ€Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1195-1205.	2.0	10
6	Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 528-539.	2.0	26
7	Exposureâ€response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 977-986.	2.3	5
8	An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Antiâ€EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1225-1235.	2.0	9